AesMed Korea

09/05/2026

New Blog Series Now Live: SCALPORIN™ R1

At AesMed, professional scalp care is more than a single product or procedure. It is about connecting active ingredient science, delivery logic, and clinical workflow into a more complete treatment approach.

That is why we are introducing our new 3-part blog series on SCALPORIN™ R1, AesMed’s professional electroporation scalp device.

In this series, we explore:

✅ Why delivery matters in professional scalp care
✅ How electroporation supports non-invasive, needle-free treatment
✅ What makes SCALPORIN™ R1 a premium professional solution
✅ How SCALPORIN™ R1 may complement professional scalp solutions such as AGF39
✅ How it fits within CytoMesopecia – Cytokines Mesotherapy for Alopecia, AesMed’s structured concept for cytokines-based scalp treatment

If you are a dermatologist, hair restoration professional, aesthetic physician, clinic, or professional scalp care partner, this series offers a closer look at how device technology, solution design, and treatment philosophy can work together in modern scalp care.

Read the series and discover the professional logic behind SCALPORIN™ R1.

https://aesmed.blog/why-delivery-matters-in-scalp-care-electroporation-active-solutions-and-the-logic-behind-professional-treatment/

27/04/2026

📢 Meet AesMed at KSHRS 2026

AesMed is pleased to participate in the 18th Annual Meeting of the Korean Society of Hair Restoration Surgery (KSHRS) 2026,
a leading academic event in the field of hair restoration.

📅 May 10, 2026 (Sunday)
⏰ 9:00 AM – 6:00 PM
📍 Grand InterContinental Seoul Parnas
📍 Orchid & Chrysanthemum Hall

At the conference, AesMed will present its latest innovations in science-based alopecia treatment, including:

🔬 CytoMesopecia – Cytokines Mesotherapy for Alopecia
🧬 AGF39 cytokine-based solution
🧴 Advanced scalp care solutions

Join us to explore how cytokine science and regenerative approaches are shaping the future of hair restoration.

We look forward to connecting with surgeons, dermatologists, and industry professionals.

21/04/2026

📢 Meet AesMed at KALDAT 2026

AesMed is excited to announce our participation in the
Korean Association for Laser, Dermatology and Trichology (KALDAT) 2026 Conference.

📅 May 3, 2026 (Sunday)
📍 COEX, Hall C (3rd Floor), Seoul
📍 Booth C37

At our booth, we will showcase our latest innovations in hair-loss treatment, including:

🔬 CytoMesopecia – Cytokines Mesotherapy for Alopecia
🧬 AGF39 cytokine-based solution
🧴 4th Generation Advance Follicle Shampoo

Join us to explore how science-driven solutions are shaping the future of alopecia care.

We look forward to connecting with dermatologists, hair restoration specialists, and global partners.

👉 Visit us at Booth C37

15/04/2026

🌟 AesMed is excited to support the upcoming Hair Symposium: From Root to Result – Evidence-Based Solutions for Hair Restoration in Malaysia!

Hosted by AesMed’s exclusive distributor in Malaysia, this special symposium will bring together Malaysian doctors and medical professionals for an inspiring exchange of the latest insights in hair restoration and scalp health.

AesMed will introduce a Korean KOL physician to deliver a special lecture and hands-on clinical session on CytoMesopecia using AGF39. This is a valuable opportunity for Malaysian doctors to explore the practical treatment approach, clinical application, and professional value of AesMed’s cytokines-based hair restoration solution.

🎤 Featured speakers:
Dr Wan Syazli – Plastic Surgeon, Malaysia
Dr Seungjong Lee – Plastic Surgeon, Korea

✨ From surgical expertise to non-surgical innovation, this symposium is designed to highlight the future of evidence-based hair restoration.

📍 Date: 19 April 2026
⏰ Time: 10:00 AM – 2:00 PM
🏥 Venue: MAHSA Specialist Hospital, Selangor, Malaysia

AesMed looks forward to sharing knowledge, building stronger medical partnerships, and advancing the future of hair restoration together.

10/04/2026

How SGF57 Built Trust - From Conferences to Credibility : Part 3 (Final) is Live

Credibility isn’t built with claims. It’s built with evidence over time.

In the final post of our SGF57 series, we show how SGF57’s reliability story grew through:
✅ 2013–2014 scientific conference posters (real-world clinical insights)
✅ protocol refinement (including 0.5 mm vs 0.3 mm microneedle depth)
✅ the value of peer-reviewed publication (transparent methods, measurement, safety, and limitations)

This is the evidence-first mindset that supports AesMed’s approach and the credibility story behind AGF39.

🔗 Read Part 3 on the AesMed Official Blog
https://aesmed.blog/from-conference-posters-to-credibility-how-sgf57-built-trust-series-part-3/

That is the story of SGF57, often described as the original blueprint behind AesMed’s later evidence-driven approaches, including AGF39. In this final post of

05/04/2026

🔬 AesMed Successfully Concludes KIMES 2026

AesMed successfully participated in KIMES 2026, one of Asia’s leading medical exhibitions, held in Seoul.

At Booth A816, we showcased our latest innovations in hair-loss treatment, including:
• CytoMesopecia – Cytokines Mesotherapy for Alopecia
• AGF39 cytokine-based solution
• 4th Generation Advance Follicle Shampoo

We were honored to connect with global healthcare professionals, partners, and industry leaders, receiving strong interest in our science-based approach to alopecia care.

🌏 This exhibition marks another step forward in expanding AesMed’s global presence.

Thank you to everyone who visited us—we look forward to future collaborations!

🌐 Visit Our YouTube : https://youtu.be/Xj78u59NEI4?si=G3xmblsaTTcuNaQK

🔎Learn more about [AGF39™]- https://aesmed.blog/agf39-clinical-experience-real-world-data-and-global-adoption-part-4/"Leading Korea's hair loss solutions. N...

29/03/2026

Part 2 is Now Live: The Clinical Study Behind the Original SGF57 Formula

At AesMed, credibility starts with clinical structure, a clear study design, a defined protocol, and measurable outcomes.

We’ve just published Part 2 of our SGF57 official blog series, featuring a peer-reviewed pilot clinical study that explored a growth-factor topical approach supported by microneedling delivery in female pattern hair loss (FPHL).

✅ What this post covers (in plain language)
• Study design: scalp-split, single-blinded, placebo-controlled
• Participants: a small FPHL pilot group
• Protocol: topical SGF57 + microneedling delivery (0.5 mm), once a week for 5 weeks
• Measurement: imaging-based assessment (phototrichogram) focusing on hair density (hair shaft counts)
• Key observations: improvement was observed on the treated side (10%+ vs baseline reported in the study)
• Safety: no treatment-related adverse reactions reported; discomfort described as mild

🔎 Why it matters
This post is not about promises, it’s about how evidence is built.
By explaining the study step-by-step (design → method → outcomes → safety → meaning), we aim to help both readers and professionals understand what was tested and what the findings may suggest.

📖 Read Part 2 on the AesMed Official Blog
https://aesmed.blog/the-clinical-study-behind-the-original-sgf57-formula-series-part-2/

Up next: Part 3 - From Conference Posters to Credibility: How SGF57 Built Trust (2013–2014)

This study is closely connected to the origin story of SGF57, the original blueprint behind AesMed’s evidence-first approach.

19/03/2026

SGF57 in 3 Parts: The Evidence Story Behind AGF39 (Clinical → Conference → Journal)

We’re excited to share a new 3-part series on the AesMed Official Blog featuring SGF57 - the original formula that helped shape AesMed’s evidence-first approach and the credibility story behind AGF39.

This series is written for both hair-loss–interested readers and medical professionals, translating clinical and academic evidence into clear, accessible insights without overclaiming.

📌 Series Theme: Evidence Continuity (Clinical → Conference → Journal)
Across three posts, we explore how SGF57 was studied, measured, and shared through scientific channels.

✅ What’s Inside the Series
Part 1. SGF57: The Original Blueprint Behind AGF39
• The origin story of SGF57 and why “growth factors + delivery” became essential

Part 2. The Clinical Study Behind the Original SGF57 Formula
• A plain-language walkthrough of a peer-reviewed pilot study in female pattern hair loss (FPHL)
• Study design, protocol, measured outcomes, and safety observations

Part 3. From Conference Posters to Credibility: How SGF57 Built Trust
• How academic posters (2013–2014) expanded clinical insight
• Protocol optimization highlights, including microneedle depth, and why journals matter

🔗 Read the full series on the AesMed Official Blog.
https://aesmed.blog/sgf57-the-original-blueprint-behind-agf39-series-part-1/

For clinics and professional partners who would like an evidence-focused briefing pack, please contact us through our official inquiry channel.

Discover SGF57, the original formula behind AGF39, and how “growth factors + microneedling delivery” evolved into clinical, conference, and peer-reviewed

10/03/2026

🔬 AGF39: Clinical Experience, Real-World Data, and Global Adoption

Korean Cytokines Mesotherapy for Hair Regrowth – Part 4
In the final part of our blog series on Korean Cytokines Mesotherapy for Hair Regrowth, we explore the clinical experience and global adoption of AGF39, AesMed’s proprietary cytokine-based solution for professional alopecia care.

AGF39 has been widely used in hair-loss treatment hospitals and specialized clinics across Korea, Japan, China, and other regions, accumulating extensive real-world clinical experience and high procedure volume.

Through its integration with
CytoMesopecia – Cytokines Mesotherapy for Alopecia,
AGF39 helps support follicular regeneration, maintain the anagen phase, and improve the scalp microenvironment for effective hair regrowth strategies.

🌏 With growing adoption in the global hair-loss treatment field, AGF39 continues to strengthen its credibility through clinical application, practitioner experience, and scientific understanding of cytokine signaling in hair biology.

📖 Read the full article on our official blog
🔗 https://aesmed.blog/agf39-clinical-experience-real-world-data-and-global-adoption-part-4/

AGF39: Clinical Experience, Real-World Data, and Global Adoption

04/03/2026

📢 Meet AesMed at KIMES 2026

AesMed is excited to announce our participation in KIMES 2026 – The 41st Korea International Medical & Hospital Equipment Show, one of Asia’s leading medical exhibitions.
At this exhibition, AesMed will introduce its latest innovations in hair-loss treatment and regenerative scalp care, including:

🔬 CytoMesopecia – Cytokines Mesotherapy for Alopecia
🧬 AGF39 cytokine-based clinical solution
🧴 Advance Follicle Shampoo for professional scalp care

We warmly invite healthcare professionals, industry partners, and global visitors to meet our team and explore new opportunities for collaboration.

📍 Booth No.: A816
📅 March 19 – 22, 2026
📍 COEX Convention & Exhibition Center, Seoul

Opening Hours
• Mar 19 – 21 : 10:00 AM – 6:00 PM
• Mar 22 : 10:00 AM – 5:00 PM

Learn more about the exhibition:
🔗 https://kimes.kr/eng/exhibitor/detail/2068692591_2026_kor

We look forward to welcoming you at AesMed Booth A816.

24/02/2026

CytoMesopecia: Turning Cytokine Science into a Reproducible Clinical Framework (Part 3)

In cytokines mesotherapy, one key challenge has become clear in real-world practice:
How do we translate cytokine science into a structured, consistent, and clinically meaningful protocol?

AesMed’s answer is CytoMesopecia – Cytokines Mesotherapy for Alopecia, a proprietary framework designed to move beyond ad-hoc sessions and support standardized, scalable, long-term care.

What CytoMesopecia focuses on
• Biological modulation (not overstimulation) : Supports balanced cytokine signaling for sustainable regrowth
• Targeted dermal delivery : Mesotherapy delivery to the scalp dermis for localized effectiveness
• Integration with clinical practice : Designed to complement pharmacotherapy, PRP, devices, and post-transplant care

Clinical application logic
• Scalp & follicular assessment
• Interval planning and consistent protocol use
• Monitoring + adjustment based on patient response
• Positioning cytokines mesotherapy as a platform therapy, not a one-time procedure

Up next (Part 4): AGF39
CytoMesopecia created the need for a cytokine solution aligned with balance, precision, and usability—leading to AGF39, AesMed’s proprietary cytokine solution.

👉 Read Part 3 here: https://aesmed.blog/cytomesopecia-cytokines-mesotherapy-for-alopecia/

Blog Series Part 3